We have created an nQuery Advisor user group for clinical trials on linkedIn.
The group has been created for exiting and future users of nQuery Advisor working in clinical trials to connect, support, share ideas, seek advice and draw from one anothers experiences.
The first discussion stems from the news that shares in Intercept Pharmaceuticals surged as much as 218 percent after the company reported that the mid-stage FLINT trial of obeticholic acid for the treatment of nonalcoholic steatohepatitis (NASH) was stopped early due to meeting its main goal. We ask the question, could interim analysis enable early stopping for efficacy, thus saving time, money and many other resources?
To visit the new user group for clinical trials or comment on this discussion please Click Here